A2a Receptor Antagonist Timing for Levodopa Dyskinesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease using levodopa often lead to levodopa-induced dyskinesias, a disabling side effect with no effective pharmacotherapy other than surgery, necessitating a need for alternative approaches to manage neurodegenerative disorders without inducing dyskinesia.
Innovation Solution
Administering an A2a receptor antagonist at a time delay after levodopa administration, when plasma levodopa levels are low, to reduce the occurrence of levodopa-induced dyskinesias, and potentially co-administering with other therapeutic agents like dopamine agonists or MAO-B inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa is administered at high concentrations to achieve symptomatic relief in Parkinson's disease, then motor symptoms are effectively treated, but levodopa-induced dyskinesias emerge as a disabling side effect
Solution Approach 1:
The patent introduces A2a receptor antagonists as intermediary substances that mediate between levodopa's therapeutic effects and its harmful side effects. The antagonist blocks A2a receptors in the striatum, preventing the development of dyskinesias while allowing levodopa to maintain dopamine levels for symptom relief. This intermediary approach decouples the therapeutic benefit from the harmful effect.
Solution Approach 2:
The patent changes the pharmacological parameter by introducing a second agent (A2a antagonist) that modifies the neural circuit dynamics. By blocking A2a receptors, the system alters the synaptic plasticity parameters in the basal ganglia, preventing the maladaptive changes that lead to dyskinesias while preserving the beneficial dopamine replacement effects of levodopa.
2Object-affected harmful factors
If A2a receptor antagonists are co-administered with levodopa, then levodopa-induced dyskinesias are reduced, but the treatment complexity increases
Solution Approach 1:
The patent segments the treatment approach by separating the dopamine replacement function (levodopa) from the dyskinesia prevention function (A2a antagonist). This segmentation allows each agent to perform its specific role optimally, with levodopa addressing motor symptoms and the antagonist preventing side effects, thereby managing complexity through functional division.
Solution Approach 2:
The A2a receptor antagonist serves multiple functions: it prevents dyskinesias, potentially enhances levodopa efficacy, and may have neuroprotective effects. This multi-functionality justifies the added treatment complexity by providing multiple benefits from a single additional agent, thereby improving the overall therapeutic profile.
3Duration of action of stationary object
If levodopa is administered chronically to maintain symptom control, then long-term motor function is preserved, but disabling motor side effects develop
Solution Approach 1:
The patent applies preliminary action by administering the A2a receptor antagonist before dyskinesias can develop during chronic levodopa treatment. The antagonist pre-emptively blocks the neural mechanisms that would otherwise lead to dyskinesia formation, allowing patients to maintain long-term levodopa therapy without developing disabling side effects.
Solution Approach 2:
The patent converts the harmful overactivation of A2a receptors (which normally contributes to dyskinesia development) into a beneficial opportunity. By selectively blocking these receptors during chronic treatment, the therapy transforms a potential harm mechanism into a targeted intervention point, enabling long-term symptom control without the usual progression to dyskinesias.
Data Source
AI summary
Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor antagonists in the treatment of neurodegenerative disorders (e.g., Parkinsons disease) and the treatment and/or prevention levodopa-induced dyskinesias associated with such treatment.